hematopoietic system
• pIpC-injected mice exhibit mild myelodysplastic syndrome-like phenotype
• however, overall survival does not differ from wild-type mice
• mice show decreased frequencies of megakaryocyte/erythrocyte lineage-restricted progenitors and erythroid progenitors after pIpC injection, suggesting a blocked differentiation into erythromegakaryocyte lineages
|
• slightly enlarged spleen in pIpC-treated mice
|
• pIpC-injected mice show evidence of extramedullary hematopoiesis, with increased frequencies of erythroid progenitors in the spleen
|
• pIpC-injected mice show increased red cell distribution width, suggestive of dyerythropoiesis
|
• mature cells are skewed to myeloid lineages in pIpC-injected mice with increased granulocytes/monocytes (CD11b+) in the bone marrow and spleen
|
• mature cells are skewed to myeloid lineages in pIpC-injected mice with increased granulocytes/monocytes (CD11b+) in the bone marrow and spleen
|
• mice show a slightly decreased white blood cell count after polyinosinic-polycytidylic acid (pIpC) injection
• however, no changes in hemoglobin level or platelet count after pIpC injection
|
• mice show a large reduction of B-lymphocytes (B220+) after pIpC injection
|
• hematopoietic stem/progenitor cell pools are expanded in pIpC-injected mice
|
• the increase in LSK cells of pIpC-injected mice is most prominent in myeloid-based progenitors, including multipotent progenitor 2 and 3, followed by long-term hematopoietic stem cells and short-term hematopoietic stem cells, indicating myeloid skewing
|
• common myeloid progenitors and granulocyte-macrophage progenitors are increased in pIpC-treated mice
|
• common lymphoid progenitors are decreased in pIpC-treated mice
|
• mice show decreased frequency of erythroid progenitors after pIpC injection
|
• bone marrow of pIpC-injected mice shows higher frequency of Lin-/Sca1+/c-Kit+ (LSK) cells, where all major subfractions of LSK cells are increased
|
• mice show decreased frequencies of megakaryocyte/erythrocyte lineage-restricted progenitors following pIpC injection
|
• hematopoietic stem cells (CD150+/CD48- LSK) show a decreased frequency of apoptotic cells and an enhanced cell cycling (S/G2/M) with decreased quiescent cells after pIpC injection
• in competitive repopulation assay, cells from pIpC-injected mice show enhanced chimerism within the LSK fraction, although the chimerism is not changed in total bone marrow and even reduced in peripheral blood, particularly within lymphocytes, indicating an enhanced self-renewal and repopulation capacity of progenitors with a block in lymphoid differentiation
|
immune system
• slightly enlarged spleen in pIpC-treated mice
|
• mature cells are skewed to myeloid lineages in pIpC-injected mice with increased granulocytes/monocytes (CD11b+) in the bone marrow and spleen
|
• mature cells are skewed to myeloid lineages in pIpC-injected mice with increased granulocytes/monocytes (CD11b+) in the bone marrow and spleen
|
• mice show a slightly decreased white blood cell count after polyinosinic-polycytidylic acid (pIpC) injection
• however, no changes in hemoglobin level or platelet count after pIpC injection
|
• mice show a large reduction of B-lymphocytes (B220+) after pIpC injection
|
growth/size/body
• slightly enlarged spleen in pIpC-treated mice
|